Transcript Of Registrant's Web Site

WHAT'S GOING ON ?


Message from the President (April 1, 1998)


With the advent of the Electronic Age and the Internet, we are in a new age of communication. Just as NeoTherapeutics is on the cutting edge in biomedical science, we believe that it would be appropriate for us to try new cutting edge avenues of communication with investors and individuals who have an interest in our Company and technology. Thus, we are testing this new format for communication. This page on our website will provide a means of discussing matters of concern to our investors as well as affording the Company an opportunity to comment on issues. We also hope to be able to elaborate on different aspects of our technology from time to time. In addition to sending our shareholders quarterly reports timed to our Form 10-Q filings with the SEC, we will publish those quarterly letters on this site. It is our intent to have at least one additional posting at this site between each quarterly report. Many investors have commented to us that they have been concerned that the flow of information on the status of the Company is not generally available unless the investor continually calls the Company. Hopefully this means of communication will prove to be more convenient to our investors while providing timely information.


NeoTherapeutics has filed the Annual Report on Form 10-KSB with the SEC. It contains our audited financial statements and other important information. I would like to elaborate on two areas of that document - our clinical program and the financial status of the Company.


The first is the status of our development program. Three Phase I clinical studies have been completed. Traditionally, Phase I studies provide information necessary to design Phase II efficacy studies and are not usually published independent research projects.


The first Phase I human clinical study was conducted in Canada with 10 Alzheimer's disease volunteers and involved treatment with a single escalating oral dose of AIT-082. The volunteers received a single dose of placebo, 500, 1000, 2000 and then 4000 milligrams of AIT-082 at 3-7 day intervals. The available data from that study indicated that AIT-082 produced no serious adverse reactions, that AIT-082 was orally absorbed and remained in the blood system for sufficiently long duration to suggest the possibility that once daily dosage was possible. The results of the memory function tests suggested that lower doses of AIT-082 should be studied. To that objective, the same 10 patients enrolled in the second Phase I Canadian study in which the single doses studied were 50,


1


This page contains forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, the biological activity, side effect profile and efficacy of AIT-082, the early stage of product development, the initiation and completion of additional clinical testing and ...